[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:t-4-14":3},{"name":4,"total":5,"recruiting":6,"trials":7},"t(4;14)",5,4,[8,16,22,28,35],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06100237","Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)",[12],"Phase 2","RECRUITING","2026-08-26T02:16:24.135291Z","2026-05-05T02:43:29.197990Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05776979","Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients",[12],"2026-08-26T02:19:19.162260Z","2026-05-05T02:43:29.189075Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT05469893","Immuno-PRISM (PRecision Intervention Smoldering Myeloma)",[12],"2026-08-26T02:18:55.570428Z","2026-05-05T02:43:27.482255Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":33,"content_modified":34},"NCT03937635","Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma",[32],"Phase 3","2026-08-26T02:16:42.787115Z","2026-05-05T02:43:27.306737Z",{"nct_id":36,"title":37,"phases":38,"status":39,"updated_at":40,"content_modified":41},"NCT07029776","MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma",[12],"NOT_YET_RECRUITING","2026-08-26T02:18:08.005333Z","2026-05-05T02:43:28.128103Z"]